Contagens de células T CD4+ na co-infecção HIV-1 e HTLV-1: alta prevalência da paraparesia espástica tropical/mielopatia associada ao HTLV-1

INTRODUCTION: HIV positive patients co-infected with HTLV-1 may have an increase in their T CD4+ cell counts, thus rendering this parameter useless as an AIDS-defining event. OBJECTIVE: To study the effects induced by the co-infection of HIV-1 and HTLV-1 upon CD4+ cells. MATERIAL AND METHODS: Since 1997, our group has been following a cohort of HTLV-1-infected patients, in order to study the interaction of HTLV-1 with HIV and/or with hepatitis C virus (HCV), as well as HTLV-1-only infected asymptomatic carriers and those with tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM). One hundred and fifty HTLV-1-infected subjects have been referred to our clinic at the Institute of Infectious Diseases "Emílio Ribas", São Paulo. Twenty-seven of them were also infected with HIV-1 and HTLV-1-infection using two ELISAs and confirmed and typed by Western Blot (WB) or polymerase chain reaction (PCR). All subjects were evaluated by two neurologists, blinded to the patient's HTLV status, and the TSP/HAM diagnostic was based on the World Health Organization (WHO) classification. AIDS-defining events were in accordance with the Centers for Disease Control (CDC) classification of 1988. The first T CD4+ cells count available before starting anti-retroviral therapy are shown compared to the HIV-1-infected subjects at the moment of AIDS defining event. RESULTS: A total of 27 HIV-1/HTLV-1 co-infected subjects were identified in this cohort; 15 already had AIDS and 12 remained free of AIDS. The median of T CD4+ cell counts was 189 (98-688) cells/mm³ and 89 (53-196) cells/mm³ for co-infected subjects who had an AIDS-defining event, and HIV-only infected individuals, respectively (p = 0.036). Eight of 27 co-infected subjects (30%) were diagnosed as having a TSP/HAM simile diagnosis, and three of them had opportunistic infections but high T CD4+ cell counts at the time of their AIDS- defining event. DISCUSSION: Our results indicate that higher T CD4+ cells count among HIV-1/HTLV-1-coinfected subjects was found in 12% of the patients who presented an AIDS-defining event. These subjects also showed a TSP/HAM simile picture when it was the first manifestation of disease; this incidence is 20 times higher than that for HTLV-1-only infected subjects in endemic areas.INTRODUÇÃO: A possibilidade que a co-infecção pelo vírus da leucemia de células T humana do tipo 1 (HTLV-1) em indivíduos infectados pelo vírus da imunodeficiência humana do tipo 1 poderia falsamente elevar o número de linfócitos T CD4+ no momento do evento definidor de aids, inferindo que essa contagem poderia ser um marcador laboratorial incompleto nos pacientes com a co-infecção HIV-1/HTLV-1. OBJETIVO: Estudar a interação entre o HIV-1 e a co-infecção como o HTLV-1. MATERIAL E MÉTODO: Desde 1997, nosso grupo tem seguido uma coorte de pacientes para estudar a interação entre HIV e/ou vírus da hepatite C (HCV), como também pacientes assintomáticos ou com TSP/HAM. 150 pacientes infectados pelo HTLV-1, encaminhados à clínica de HTLV do Instituto de Infectologia Emilio Ribas, São Paulo, Brasil, foram estudados. Vinte e sete deles estavam co-infectados pelo HIV-1 e HTLV-1, usando dois ELISAs e confirmados tipados pelo WB ou PCR. Todos os pacientes foram avaliados por dois neurologistas, cegos para o status de HTLV e o diagnóstico de TSP/HAM foi baseado na classificação da Organização Mundial de Saúde, 1988. A primeira contagem de células T disponível antes da terapia anti-retroviral foi mostrada para comparar com os pacientes infectados pelo HIV no momento do evento definidor de aids de acordo com Classificação do Centro de controle de Doenças, 1988. RESULTADOS: Um total de 27 HIV-1/HTLV-1 co-infectados foram identificados na coorte, 15 já apresentavam aids e 12 permaneceram sem evento de aids. A mediana de células T CD4 foi de 189 (98-688) células/mm³ e 89 (53-196) células/mm³ nos co-infectados que tinham evento definidor de aids e naqueles com a infecção somente pelo HIV, respectivamente (p = 0,036). Oito dos 27 co-infectados (30%) foram diagnosticados tendo TSP/HAM símile, e três deles mostraram elevada contagem de células T CD4 e apresentaram infecções oportunistas no momento do evento definidor de aids. DISCUSSÃO: Nossos resultados indicam que a contagem de células T CD4+ entre os indivíduos com HIV-1/HTLV-1 foi somente discrepante em 12% desses pacientes e podem ser relacionados à progressão da infecção HTLV-1, e todos mostraram um quadro de TSP/HAM símile como a primeira manifestação de doença. Entretanto, essa taxa de ataque foi 20 vezes mais alta que a observada em pacientes somente infectados pelo HTLV-1 em área endêmica

Aspectos clínicos e epidemiológicos da infecção pelo vírus linfotrópico de células T humanas do tipo 2 (HTLV-II) em São Paulo, Brasil: presença de paraparesia espástica tropical/mielopatia associada ao HTLV em pacientes co-infectados pelo HIV-1

In this study, the epidemiological and clinical features observed in solely HTLV-II-infected individuals were compared to those in patients co-infected with HIV-1. A total of 380 subjects attended at the HTLV Out-Patient Clinic in the Institute of Infectious Diseases "Emilio Ribas" (IIER), São Paulo, Brazil, were evaluated every 3-6 months for the last seven years by infectious disease specialists and neurologists. Using a testing algorithm that employs the enzyme immuno assay, Western Blot and polymerase chain reaction, it was found that 201 (53%) were HTLV-I positive and 50 (13%) were infected with HTLV-II. Thirty-seven (74%) of the HTLV-II reactors were co-infected with HIV-1. Of the 13 (26%) solely HTLV-II-infected subjects, urinary tract infection was diagnosed in three (23%), one case of skin vasculitis (8%) and two cases of lumbar pain and erectile dysfunction (15%), but none myelopathy case was observed. Among 37 co-infected with HIV-1, four cases (10%) presented with tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) simile. Two patients showed paraparesis as the initial symptom, two cases first presented with vesical and erectile disturbances, peripheral neuropathies were observed in other five patients (13%), and seven (19%) patients showed some neurological signal or symptoms, most of them with lumbar pain (five cases). The results obtained suggest that neurological manifestations may be more frequent in HTLV-II/HIV-1-infected subjects than those infected with HTLV-II only.Neste estudo, as características epidemiológicas e clínicas observadas nos indivíduos infectados pelo HTLV-II foram comparadas com os pacientes co-infectados com HIV-1. Um total de 380 indivíduos atendidos na clínica do Ambulatório HTLV do Instituto de Infectologia "Emilio Ribas" (IIER), São Paulo, Brasil, foram avaliados a cada 3-6 meses nos últimos sete anos por especialistas em doenças infecciosas e neurologistas. Usando um algoritmo que emprega ensaio imunoenzimático, Western Blot e reação em cadeia de polimerase, foram incluídos 201 (53%) pacientes infectados pelo HTLV-I e 50 (13%) infectados pelo HTLV-II. Trinta e sete (74%) eram co-infectados pelo HTLV-II e HIV-1. Dos 13 (26%) indivíduos unicamente infectados pelo HTLV-II, infecção do trato urinário foi diagnosticada em três, um com vasculite e em dois casos dor lombar e disfunção erétil mas nenhum caso de mielopatia foi observado. Entre 37 pacientes co-infectados com HIV-1, quatro (10%) casos apresentaram com paraparesia espástica tropical/mielopatia associada ao HTLV similar. Dois casos mostraram paraparesia como sintoma inicial, dois outros casos se apresentaram primeiramente com distúrbios vesical e erétil e as neuropatias periféricas foram observadas em cinco pacientes (13%). Outros sete (19%) pacientes mostraram algum sinal ou sintoma neurológico, a maioria deles com dor lombar (cinco casos). Os resultados sugerem que as manifestações neurológicas podem ser mais freqüentes em indivíduos co-infectados pelo HTLV-II/HIV-1 do que nos indivíduos infectados somente pelo HTLV-II

HIV/Leishmania co-infection: clinical manifestations in a serie of cases

Em áreas endêmicas para leishmaniose visceral, a AIDS aumenta o risco de aparecimento desta doença de cem a mil vezes. Conhecem-se muitos estudos sobre leishmaniose visceral (LV) em HIV/AIDS no Mediterrâneo, mas, pouco sobre leishmaniose tegumentar (LT) em HIV/AIDS. No Brasil não se constatou, até o momento, um aumento de casos de co-infecção HIV-Leishmania, mas, isto pode ser conseqüente ao subdiagnóstico por várias causas incluindo o não conhecimento da apresentação clínica nesses casos. Pela prevalência maior da LT em relação à LV no Brasil, é de se supor que ocorram com freqüência casos de co-infecção com a forma tegumentar de leishmaniose no nosso meio. Como no Brasil não dispomos de estudos de descrição sistemática da apresentação clínica nos casos de co-infecção, um parâmetro importante visando o diagnóstico, realizou-se um estudo transversal e descritivo, durante um período de dois anos a partir de fevereiro de 2002, em dois centros de tratamento de doenças infecciosas em São Paulo. Partimos de uma população alvo de 113 pacientes com sorologia positiva para HIV, procedentes de área endêmica para leishmanioses, 69 com algum sintoma sugestivo de leishmaniose visceral ou tegumentar e 44 assintomáticos. Em dez pacientes foi diagnosticada leishmaniose por encontro de parasitos ou antígeno de Leishmania em tecidos, maioria (8/10) por busca ativa, sendo cinco casos de LV e cinco de LT. Baseados nesses casos, observamos que, o contato com área endêmica de leishmaniose mesmo por um período curto como duas semanas deva ser valorizado, principalmente se foi recente. Houve dificuldade no encontro de casos porque a leishmaniose não é considerado como diagnóstico diferencial de infecções intercorrentes nos casos de HIV/AIDS no nosso meio, houve presença concomitante de outras doenças oportunistas mais prevalentes e manifestações clínicas atípicas ou semelhantes a infecções oportunistas. xvi Os casos de LV apresentaram manifestações clássicas, enquanto que os casos de LT apresentaram lesões diversas, desde úlcera única até lesões múltiplas e polimórficas (placas infiltrativas, pápulas, nódulos, máculas), com tendência à disseminação atingindo mucosa e pele, incluindo área genital (em quatro dos cinco pacientes com LT). Em dois pacientes observaram-se aparecimento de lesões (num caso) e piora (noutro caso), após início da terapia antirretroviral altamente efetiva (HAART), com características sugestivas de síndrome inflamatória de recuperação imune. Quanto à classificação de HIV segundo CDC, oito pacientes eram C3 e dois B3 e todos apresentavam contagem de linfócitos T CD4+ menor que 200 células/?l. A sorologia para leishmaniose foi positiva em todos os casos de LV mas, positiva em três dos cinco casos de LT. O teste de Montenegro foi negativo nos dois casos de LV onde o teste foi realizado e positivo em todos os três pacientes de LT submetidos ao teste. No tratamento da leishmaniose, freqüentemente os pacientes apresentaram efeitos adversos aos medicamentos e obervou-se mortalidade alta (40%) e freqüência alta de recidiva nos pacientes sobreviventes (100% dos LT e 66% dos LV)In endemic areas of visceral leishmaniasis (VL), AIDS increases the risk for VL in 100 to 1000 times. There are many studies on VL in HIV/AIDS patients from the Mediterranean basin but data on tegumentary leishmaniasis (TL) are scarce. In Brazil, no increase in the number of cases of HIV/Leishmania co-infection was reported so far, but it may be due to subdiagnosis owing to various reasons including ignorance on clinical features of the co-infected patients.. Since the prevalence of TL is greater than VL in Brazil, we presume that cutaneous or mucosal leishmaniasis would be frequent in cases of coinfection in our country. Since there are no studies on systematic description of clinical manifestations of HIV/Leishmania co-infection in Brazil, an important basis for diagnosis, study was done for a period of two years from February 2002 aiming description of clinical manifestations in a transversal study in two infectious disease reference centers in Sao Paulo city, Brazil. The target population was constituted by 113 HIV positive patients that reported some kind of contact with endemic area for leishmaniasis, 69 being with some symptoms suggestive of visceral or tegumentary leishmaniasis, and 44 asymptomatic. In ten patients diagnosis of leishmaniasis was established by the detection of amatigotes or Leishmania antigens in tissue samples, five presented VL and five TL. Eight of 10 were found by active search. Based in these cases, we noted that contact with endemic area, even for short time like two weeks has to be considered in the diagnosis, mainly if it occurred recently. The search for these cases were difficult because leishmaniasis is not considered within differential diagnosis ofopportunistic infections in HIV positive patients among physicians, and in addition more prevalent opportunistic infections were concomitantly present and the clinical features were atypical for leishmaniasis or similar to other opportunistic infections. Clinical manifestation of VL was classic, while that of TL was quite variable, ranging from single to multiple ulcers, with polimorphic xviii presentations (papules, nodules, infiltrative plaques, macules) that tended to disseminate to the other areas of skin and mucosa, including genital area (in four from five TL patients). In two patients appearance of lesions (in one case) and worsening of tegumentary manifestations (in another case) after introduction of highly active anti-retroviral therapy (HAART) were observed that were suggestive of the so called immune reconstitution inflammatory syndrome. Concerning CDC classification of HIV, eight patients were C3 and two B3, and all presented CD4+ T cell count lower than 200/?l. All the VL patients had anti-Leishmania antibody test positive, however in TL three of five cases of was positive. Leishmanin skin (Montenegro) test was negative in two cases of VL submitted to this test, and positive in all three TL patients evalued. Frequent toxicity and adverse events with treatments were observed, as well as high mortality (40%), and high frequency of relapses among survivors (100% of TL and 66% of VL cases

HIV/Leishmania co-infection: clinical manifestations in a serie of cases

Em áreas endêmicas para leishmaniose visceral, a AIDS aumenta o risco de aparecimento desta doença de cem a mil vezes. Conhecem-se muitos estudos sobre leishmaniose visceral (LV) em HIV/AIDS no Mediterrâneo, mas, pouco sobre leishmaniose tegumentar (LT) em HIV/AIDS. No Brasil não se constatou, até o momento, um aumento de casos de co-infecção HIV-Leishmania, mas, isto pode ser conseqüente ao subdiagnóstico por várias causas incluindo o não conhecimento da apresentação clínica nesses casos. Pela prevalência maior da LT em relação à LV no Brasil, é de se supor que ocorram com freqüência casos de co-infecção com a forma tegumentar de leishmaniose no nosso meio. Como no Brasil não dispomos de estudos de descrição sistemática da apresentação clínica nos casos de co-infecção, um parâmetro importante visando o diagnóstico, realizou-se um estudo transversal e descritivo, durante um período de dois anos a partir de fevereiro de 2002, em dois centros de tratamento de doenças infecciosas em São Paulo. Partimos de uma população alvo de 113 pacientes com sorologia positiva para HIV, procedentes de área endêmica para leishmanioses, 69 com algum sintoma sugestivo de leishmaniose visceral ou tegumentar e 44 assintomáticos. Em dez pacientes foi diagnosticada leishmaniose por encontro de parasitos ou antígeno de Leishmania em tecidos, maioria (8/10) por busca ativa, sendo cinco casos de LV e cinco de LT. Baseados nesses casos, observamos que, o contato com área endêmica de leishmaniose mesmo por um período curto como duas semanas deva ser valorizado, principalmente se foi recente. Houve dificuldade no encontro de casos porque a leishmaniose não é considerado como diagnóstico diferencial de infecções intercorrentes nos casos de HIV/AIDS no nosso meio, houve presença concomitante de outras doenças oportunistas mais prevalentes e manifestações clínicas atípicas ou semelhantes a infecções oportunistas. xvi Os casos de LV apresentaram manifestações clássicas, enquanto que os casos de LT apresentaram lesões diversas, desde úlcera única até lesões múltiplas e polimórficas (placas infiltrativas, pápulas, nódulos, máculas), com tendência à disseminação atingindo mucosa e pele, incluindo área genital (em quatro dos cinco pacientes com LT). Em dois pacientes observaram-se aparecimento de lesões (num caso) e piora (noutro caso), após início da terapia antirretroviral altamente efetiva (HAART), com características sugestivas de síndrome inflamatória de recuperação imune. Quanto à classificação de HIV segundo CDC, oito pacientes eram C3 e dois B3 e todos apresentavam contagem de linfócitos T CD4+ menor que 200 células/?l. A sorologia para leishmaniose foi positiva em todos os casos de LV mas, positiva em três dos cinco casos de LT. O teste de Montenegro foi negativo nos dois casos de LV onde o teste foi realizado e positivo em todos os três pacientes de LT submetidos ao teste. No tratamento da leishmaniose, freqüentemente os pacientes apresentaram efeitos adversos aos medicamentos e obervou-se mortalidade alta (40%) e freqüência alta de recidiva nos pacientes sobreviventes (100% dos LT e 66% dos LV)In endemic areas of visceral leishmaniasis (VL), AIDS increases the risk for VL in 100 to 1000 times. There are many studies on VL in HIV/AIDS patients from the Mediterranean basin but data on tegumentary leishmaniasis (TL) are scarce. In Brazil, no increase in the number of cases of HIV/Leishmania co-infection was reported so far, but it may be due to subdiagnosis owing to various reasons including ignorance on clinical features of the co-infected patients.. Since the prevalence of TL is greater than VL in Brazil, we presume that cutaneous or mucosal leishmaniasis would be frequent in cases of coinfection in our country. Since there are no studies on systematic description of clinical manifestations of HIV/Leishmania co-infection in Brazil, an important basis for diagnosis, study was done for a period of two years from February 2002 aiming description of clinical manifestations in a transversal study in two infectious disease reference centers in Sao Paulo city, Brazil. The target population was constituted by 113 HIV positive patients that reported some kind of contact with endemic area for leishmaniasis, 69 being with some symptoms suggestive of visceral or tegumentary leishmaniasis, and 44 asymptomatic. In ten patients diagnosis of leishmaniasis was established by the detection of amatigotes or Leishmania antigens in tissue samples, five presented VL and five TL. Eight of 10 were found by active search. Based in these cases, we noted that contact with endemic area, even for short time like two weeks has to be considered in the diagnosis, mainly if it occurred recently. The search for these cases were difficult because leishmaniasis is not considered within differential diagnosis ofopportunistic infections in HIV positive patients among physicians, and in addition more prevalent opportunistic infections were concomitantly present and the clinical features were atypical for leishmaniasis or similar to other opportunistic infections. Clinical manifestation of VL was classic, while that of TL was quite variable, ranging from single to multiple ulcers, with polimorphic xviii presentations (papules, nodules, infiltrative plaques, macules) that tended to disseminate to the other areas of skin and mucosa, including genital area (in four from five TL patients). In two patients appearance of lesions (in one case) and worsening of tegumentary manifestations (in another case) after introduction of highly active anti-retroviral therapy (HAART) were observed that were suggestive of the so called immune reconstitution inflammatory syndrome. Concerning CDC classification of HIV, eight patients were C3 and two B3, and all presented CD4+ T cell count lower than 200/?l. All the VL patients had anti-Leishmania antibody test positive, however in TL three of five cases of was positive. Leishmanin skin (Montenegro) test was negative in two cases of VL submitted to this test, and positive in all three TL patients evalued. Frequent toxicity and adverse events with treatments were observed, as well as high mortality (40%), and high frequency of relapses among survivors (100% of TL and 66% of VL cases

T CD4+ cells count among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): high prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM) Contagens de células T CD4+ na co-infecção HIV-1 e HTLV-1: alta prevalência da paraparesia espástica tropical/mielopatia associada ao HTLV-1

INTRODUCTION: HIV positive patients co-infected with HTLV-1 may have an increase in their T CD4+ cell counts, thus rendering this parameter useless as an AIDS-defining event. OBJECTIVE: To study the effects induced by the co-infection of HIV-1 and HTLV-1 upon CD4+ cells. MATERIAL AND METHODS: Since 1997, our group has been following a cohort of HTLV-1-infected patients, in order to study the interaction of HTLV-1 with HIV and/or with hepatitis C virus (HCV), as well as HTLV-1-only infected asymptomatic carriers and those with tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM). One hundred and fifty HTLV-1-infected subjects have been referred to our clinic at the Institute of Infectious Diseases "Emílio Ribas", São Paulo. Twenty-seven of them were also infected with HIV-1 and HTLV-1-infection using two ELISAs and confirmed and typed by Western Blot (WB) or polymerase chain reaction (PCR). All subjects were evaluated by two neurologists, blinded to the patient's HTLV status, and the TSP/HAM diagnostic was based on the World Health Organization (WHO) classification. AIDS-defining events were in accordance with the Centers for Disease Control (CDC) classification of 1988. The first T CD4+ cells count available before starting anti-retroviral therapy are shown compared to the HIV-1-infected subjects at the moment of AIDS defining event. RESULTS: A total of 27 HIV-1/HTLV-1 co-infected subjects were identified in this cohort; 15 already had AIDS and 12 remained free of AIDS. The median of T CD4+ cell counts was 189 (98-688) cells/mm³ and 89 (53-196) cells/mm³ for co-infected subjects who had an AIDS-defining event, and HIV-only infected individuals, respectively (p = 0.036). Eight of 27 co-infected subjects (30%) were diagnosed as having a TSP/HAM simile diagnosis, and three of them had opportunistic infections but high T CD4+ cell counts at the time of their AIDS- defining event. DISCUSSION: Our results indicate that higher T CD4+ cells count among HIV-1/HTLV-1-coinfected subjects was found in 12% of the patients who presented an AIDS-defining event. These subjects also showed a TSP/HAM simile picture when it was the first manifestation of disease; this incidence is 20 times higher than that for HTLV-1-only infected subjects in endemic areas.<br>INTRODUÇÃO: A possibilidade que a co-infecção pelo vírus da leucemia de células T humana do tipo 1 (HTLV-1) em indivíduos infectados pelo vírus da imunodeficiência humana do tipo 1 poderia falsamente elevar o número de linfócitos T CD4+ no momento do evento definidor de aids, inferindo que essa contagem poderia ser um marcador laboratorial incompleto nos pacientes com a co-infecção HIV-1/HTLV-1. OBJETIVO: Estudar a interação entre o HIV-1 e a co-infecção como o HTLV-1. MATERIAL E MÉTODO: Desde 1997, nosso grupo tem seguido uma coorte de pacientes para estudar a interação entre HIV e/ou vírus da hepatite C (HCV), como também pacientes assintomáticos ou com TSP/HAM. 150 pacientes infectados pelo HTLV-1, encaminhados à clínica de HTLV do Instituto de Infectologia Emilio Ribas, São Paulo, Brasil, foram estudados. Vinte e sete deles estavam co-infectados pelo HIV-1 e HTLV-1, usando dois ELISAs e confirmados tipados pelo WB ou PCR. Todos os pacientes foram avaliados por dois neurologistas, cegos para o status de HTLV e o diagnóstico de TSP/HAM foi baseado na classificação da Organização Mundial de Saúde, 1988. A primeira contagem de células T disponível antes da terapia anti-retroviral foi mostrada para comparar com os pacientes infectados pelo HIV no momento do evento definidor de aids de acordo com Classificação do Centro de controle de Doenças, 1988. RESULTADOS: Um total de 27 HIV-1/HTLV-1 co-infectados foram identificados na coorte, 15 já apresentavam aids e 12 permaneceram sem evento de aids. A mediana de células T CD4 foi de 189 (98-688) células/mm³ e 89 (53-196) células/mm³ nos co-infectados que tinham evento definidor de aids e naqueles com a infecção somente pelo HIV, respectivamente (p = 0,036). Oito dos 27 co-infectados (30%) foram diagnosticados tendo TSP/HAM símile, e três deles mostraram elevada contagem de células T CD4 e apresentaram infecções oportunistas no momento do evento definidor de aids. DISCUSSÃO: Nossos resultados indicam que a contagem de células T CD4+ entre os indivíduos com HIV-1/HTLV-1 foi somente discrepante em 12% desses pacientes e podem ser relacionados à progressão da infecção HTLV-1, e todos mostraram um quadro de TSP/HAM símile como a primeira manifestação de doença. Entretanto, essa taxa de ataque foi 20 vezes mais alta que a observada em pacientes somente infectados pelo HTLV-1 em área endêmica

Presence of tropical spastic paraparesis/human T‐cell lymphotropic virus type 1‐associated myelopathy (TSP/HAM)‐like among HIV‐1‐infected patients

Human immunodeficiency virus type 1 (HIV‐1) and human T‐cell lymphotropic virus types 1 and 2 (HTLV‐1 and ‐2) are retroviruses that share similar routes of transmission and some individuals may have a dual infection. These co‐infected subjects may be at increased risk for tropical spastic paraparesis/HTLV‐1‐associated myelopathy (TSP/HAM)‐like. To study the prevalence of tropical spastic paraparesis/HTLV‐1‐associated myelopathy (TSP/HAM) among co‐infected HIV‐1/HTLV‐1 subjects. Since July 1997, our group has been following a cohort to study the interaction of HTLV with HIV and/or hepatitis C virus (HCV), as well as HTLV‐1‐only infected asymptomatic carriers or those already presenting with TSP/HAM. During these 9 years, 296 HTLV‐1‐infected individuals were identified from a total of 538 patients who were referred to our clinic at the Institute of Infectious Diseases “Emílio Ribas,” in São Paulo, Brazil. All subjects were evaluated by two neurologists, blinded to the HTLV status. TSP/HAM diagnosis was based on Kagoshima diagnostic criteria. Results: A total of 38 HIV‐1/HTLV‐1 co‐infected subjects were identified in this cohort: Twenty‐six had already been diagnosed with AIDS and 12 remained asymptomatic. Six of 38 co‐infected subjects (18%) were diagnosed as having TSP/HAM and also AIDS, and for 5 of them TSP/HAM was their first illness. One additional incident case was diagnosed after 2 years of follow‐up. No modifications on HIV‐1 viral load was seen. In contrast, the co‐infected with TSP/HAM‐like group showed higher HTLV‐1 proviral load (505 ± 380 vs. 97 ± 149 copies/104 PBMC, P = 0.012) than asymptomatic co‐infected subjects, respectively. The incidence of myelopathy among HIV‐1/HTLV‐1 co‐infected subjects is probably higher than among patients infected only with HTLV‐1, and related to a higher HTLV‐1 proviral load. Thus, HTLV‐1/2 screening should be done for all HIV‐1‐infected patients in areas where HTLV‐1 infection is endemic80339239

Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients

Human immunodeficiency virus type 1 (HIV-1) and human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and -2) are retroviruses that share similar routes of transmission and some individuals may have a dual infection. These co-infected subjects may be at increased risk for tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM)-like. To study the prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM) among coinfected HIV-1/HTLV-1 subjects. Since July 1997, our group has been following a cohort to study the interaction of HTLV with HIV and/or hepatitis C virus (HCV), as well as HTLV-1-only infected asymptomatic carriers or those already presenting with TSP/HAM. During these 9 years, 296 HTLV-1-infected individuals were identified from a total of 538 patients who were referred to our clinic at the Institute of Infectious Diseases ""Emilio Ribas,"" in Sao Paulo, Brazil. All subjects were evaluated by two neurologists, blinded to the HTLV status. TSP/HAM diagnosis was based on Kagoshima diagnostic criteria. Results: A total of 38 HIV-1/HTLV-1 co-infected subjects were identified in this cohort: Twenty-six had already been diagnosed with AIDS and 12 remained asymptomatic. Six of 38 co-infected subjects (18%) were diagnosed as having TSP/HAM and also AIDS, and for 5 of them TSP/HAM was their first illness. One additional incident case was diagnosed after 2 years of follow-up. No modifications on HIV-1 viral load was seen. In contrast, the co-infected with TSP/HAM-like group showed higher HTLV-1 proviral load (505 +/- 380 vs. 97 +/- 149 copies/10(4) PBMC, P= 0.012) than asymptomatic co-infected subjects, respectively. The incidence of myelopathy among HIV-1/HTLV-1 co-infected subjects is probably higher than among patients infected only with HTLV-1, and related to a higher HTLV-1 proviral load. Thus, HTLV-1/2 screening should be done for all HIV-1-infected patients in areas where HTLV-1 infection is endemic

Corticosteroid therapy in TSP/HAM patients: The results from a 10 years open cohort

Background: The use of corticosteroids for treating tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) has yielded controversial results. We report the use of corticosteroids for the treatment of TSP/HAM in an open cohort. Methods: The clinical efficacy of long-term, high dose of corticosteroid therapy was studied in thirty-nine TSP/HAM patients. Disability and motor dysfunction was evaluated based on the Disability Status Scale (DSS), Osame`s Motor Disability Scales (OMDS), and Incapacity Status Scale (ISS), before and after treatment. Treatment included use of methyl-predmisolone, 1 g/day for three days, every 3-4 months. The primary end-point was a change in the scores of the neurological scales from baseline until the fifth visit after therapy. Results: After a mean follow-up of 2.2 years and an average of four pulses per patient, we noted a significant neurological improvement, reaching 24.5% according to the ISS score. No statistically significant differences in scores according to the OMDS and DSS scales were noted. Conclusion: We observed neurological improvement with the use of corticosteroids, with physical therapy and anti spastic-drugs as adjunctive treatment. However, randomized clinical trials should be done to assess the use of corticosteroids and other potentially useful immune-based therapies for TSP/HAM treatment. (C) 2008 Elsevier B.V. All rights reserved

Clinical and epidemiological aspects of HTLV-II infection in São Paulo, Brazil: presence of Tropical Spastic Paraparesis/HTLV-Associated Myelopathy (TSP/HAM) simile diagnosis in HIV-1-co-infected subjects Aspectos clínicos e epidemiológicos da infecção pelo vírus linfotrópico de células T humanas do tipo 2 (HTLV-II) em São Paulo, Brasil: presença de paraparesia espástica tropical/mielopatia associada ao HTLV em pacientes co-infectados pelo HIV-1

In this study, the epidemiological and clinical features observed in solely HTLV-II-infected individuals were compared to those in patients co-infected with HIV-1. A total of 380 subjects attended at the HTLV Out-Patient Clinic in the Institute of Infectious Diseases "Emilio Ribas" (IIER), São Paulo, Brazil, were evaluated every 3-6 months for the last seven years by infectious disease specialists and neurologists. Using a testing algorithm that employs the enzyme immuno assay, Western Blot and polymerase chain reaction, it was found that 201 (53%) were HTLV-I positive and 50 (13%) were infected with HTLV-II. Thirty-seven (74%) of the HTLV-II reactors were co-infected with HIV-1. Of the 13 (26%) solely HTLV-II-infected subjects, urinary tract infection was diagnosed in three (23%), one case of skin vasculitis (8%) and two cases of lumbar pain and erectile dysfunction (15%), but none myelopathy case was observed. Among 37 co-infected with HIV-1, four cases (10%) presented with tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM) simile. Two patients showed paraparesis as the initial symptom, two cases first presented with vesical and erectile disturbances, peripheral neuropathies were observed in other five patients (13%), and seven (19%) patients showed some neurological signal or symptoms, most of them with lumbar pain (five cases). The results obtained suggest that neurological manifestations may be more frequent in HTLV-II/HIV-1-infected subjects than those infected with HTLV-II only.<br>Neste estudo, as características epidemiológicas e clínicas observadas nos indivíduos infectados pelo HTLV-II foram comparadas com os pacientes co-infectados com HIV-1. Um total de 380 indivíduos atendidos na clínica do Ambulatório HTLV do Instituto de Infectologia "Emilio Ribas" (IIER), São Paulo, Brasil, foram avaliados a cada 3-6 meses nos últimos sete anos por especialistas em doenças infecciosas e neurologistas. Usando um algoritmo que emprega ensaio imunoenzimático, Western Blot e reação em cadeia de polimerase, foram incluídos 201 (53%) pacientes infectados pelo HTLV-I e 50 (13%) infectados pelo HTLV-II. Trinta e sete (74%) eram co-infectados pelo HTLV-II e HIV-1. Dos 13 (26%) indivíduos unicamente infectados pelo HTLV-II, infecção do trato urinário foi diagnosticada em três, um com vasculite e em dois casos dor lombar e disfunção erétil mas nenhum caso de mielopatia foi observado. Entre 37 pacientes co-infectados com HIV-1, quatro (10%) casos apresentaram com paraparesia espástica tropical/mielopatia associada ao HTLV similar. Dois casos mostraram paraparesia como sintoma inicial, dois outros casos se apresentaram primeiramente com distúrbios vesical e erétil e as neuropatias periféricas foram observadas em cinco pacientes (13%). Outros sete (19%) pacientes mostraram algum sinal ou sintoma neurológico, a maioria deles com dor lombar (cinco casos). Os resultados sugerem que as manifestações neurológicas podem ser mais freqüentes em indivíduos co-infectados pelo HTLV-II/HIV-1 do que nos indivíduos infectados somente pelo HTLV-II